Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 8:03 PM
Ignite Modification Date:
2025-12-24 @ 8:03 PM
NCT ID:
NCT01933204
Eligibility Criteria:
Inclusion Criteria:
* Participants who complained of irregular menstrual cycle in the past 12 months, with a forward or postpone of a cycle more 7 days. At least 2 cycles were missing during the past 12 months, or reported menopause for at least 60 days.
* Reported relative perimenopausal symptoms, e.g., hot flash, insomnia, migraine, easy irritation, etc.
* Age 40-50 years.
* Not accompanied with conditions that are needed for hormone therapy, e.g., menopause after surgery, active osteoporosis.
* Willing to participate and signing the inform consent.
Exclusion Criteria:
* Had a regular menopausal cycle 3 months before this trial.
* Taking estrogen, selective serotonin reuptake inhibitor(SSRI), soy isoflavone, progesterone, Vitamin E or black cohosh in the 4 weeks before inclusion.
* receiving chemoradiotherapy.
* Agnogenic vaginal bleeding.
* Coagulation defeats, or taking anticoagulant drugs, such as warfarin, heparin, etc.
* Dermal diseases, e.g., eczema, psoriasis.
* Liver or kidney failure.
* Uncontrollable hypertension, diabetes, or thyroid diseases.
* With diabetic neuropathy, malignant cancer and mental diseases (including depression).
* Intend to gestation, in gestation period or lactation period.
* Using sedative or antianxiety drugs.
* With smoking or intemperance problems.
* Using cardiac pacemaker, or joint prosthesis.
* Low compliance.
* Benign tumor in breast.
* Family history of breast cancer.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
40 Years
Maximum Age:
55 Years
Study:
NCT01933204
Study Brief:
Protocol Section:
NCT01933204